Regarding the article “Patient safety in the administration of antineoplastic chemotherapy and of immunotherapics for oncological treatment: scoping review”, with DOI number: http://dx.doi.org/10.1590/1980-265x-tce-2018-0312, published in Texto & Contexto - Enfermagem, volume 28 in 2019, elocation e20180312

On page 10, second paragraph, where was written: “In order to avoid permanent sequelae and unnecessary tragic deaths as a result of intrathecal administration of vinca alkaloids, several procedures are recommended in institutions where intrathecal medications are administered: handling vincristine in an infusion bag (minibags), eliminating the risk of exchange with intrathecal syringes; labeling the infusion bags with vincristine preparations with an alert (where it for intrathecal use only); establishing a differentiated procedure for intrathecal drug administration, in another location and/or at times or days different from the intravenous medications (if this procedure is not possible, as for people receiving medication via both routes, a procedure must be performed so that intravenous vincristine is not dispensed until the confirmation of the end of intrathecal administration or vice versa); not using an infusion pump to infuse intrathecal vincristine (higher likelihood of leakage).^4,13”

Now read: In order to avoid permanent sequelae and unnecessary tragic deaths as a result of intrathecal administration of vinca alkaloids, several procedures are recommended in institutions where intrathecal medications are administered: handling vincristine in an infusion bag (minibags), eliminating the risk of exchange with intrathecal syringes; labeling the infusion bags with vincristine preparations with an alert (where it for intravenous use only); establishing a differentiated procedure for intrathecal drug administration, in another location and/or at times or days different from the intravenous medications (if this procedure is not possible, as for people receiving medication via both routes, a procedure must be performed so that intravenous vincristine is not dispensed until the confirmation of the end of intrathecal administration or vice versa); not using an infusion pump to infuse intravenous vincristine (higher likelihood of leakage).^4,13

On page 12, seventh paragraph, where was written: “...vincristine in an infusion bag (minibag) and not in a syringe; administering intrathecal vinca alkaloid, at a different location and/or at times or days disposing of the intravenous medicinal products (if this procedure is not possible, intravenous vincristine should not be dispensed until the confirmation of the end of intrathecal administration or vice versa).^4,13”

Now read: ...vincristine in an infusion bag (minibag) and not in a syringe; administering intravenous vinca alkaloid, at a different location and/or at times or days disposing of the intratecal medicinal products (if this procedure is not possible, intravenous vincristine should not be dispensed until the confirmation of the end of intrathecal administration or vice versa).^4,13

Publication Dates